FP6Individual fellowship2007–2009

BIOCOATING · Development a new biocoating multi-layered polyelectrolyte film with incorporated drug-loaded liposomes

FP6 — Marie Curie Actions (Human Resources and Mobility)

Duration
2007-10-01 → 2009-08-31
EU contribution
€155,929
Participants
1
Scheme
IIF

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Results in brief

Final Activity Report Summary - BIOCOATING (Development a new biocoating multilayered polyelectrolyte film with incorporated drug-loaded liposomes)

The main aim of the project was to develop a novel biocoating for controlled drug delivery, e.g. manipulated by external stimuli. This was planned to be achieved by developing stimuli-sensitive polymer films with embedded biomacromolecules or carriers, such as liposomes. The project was implemented according to the objectives in the original proposal. The summary of the performed work as a response to the three main objectives in the original proposal is given below. 1. objective 1, preparation of drug reservoirs, i.e. liposomes with controlled permeability. The stabilisation of the liposomes by polymer surface coating was introduced in the work as an efficient method to avoid vesicle rupture under contact with a solid surface. The physical chemistry of the polymer liposome stabilisation was considered. 2. objective 2, immobilisation of the liposomes on a solid surface. In the second step a new method to introduce the polymer stabilised liposomes in the biocompatible film was developed. Physico-chemical aspects of the vesicle embedding were investigated and a way to predict liposome stabilisation by polyelectrolyte coating was elaborated, showing high potential to use this system as temperature-responsible biocoating. 3. objective 3, development of approaches for controlled release of drugs from immobilised liposomes. We showed film functionalisation with a variety of bioactive nanomaterials and micromaterials, such as biomacromolecules like deoxyribonucleic acid (DNA), metal nanoparticles and polymer microcapsules). A concept of infra-red light (IR) remote release of film-immobilised materials as well as liposomes was also elaborated. The achievements of the project clearly demonstrated a high promise to use the developed stimuli-sensitive films for drug delivery applications. IR-light was a non-invasive stimulus and its use in medicine undoubtedly opened new perspectives for delivery on demand which could make medical treatment easier, efficient and more convenient for a patient. Finally, six articles in peer-reviewed scientific journals and two book sections were published based on the results of the project activity. One European patent was pending by the time of the project completion, while two manuscripts were in preparation.

Data: CORDIS, © European Union

Project objective

Temporary or permanent implants (orthopedic, cardiovascular, dental, contraception implants, devices for fracture stabilization, etc) are widely used in medicine. However, after implantation the biomaterial-associated complications like allergological and foreign body reactions, problematic tissue regeneration, and infections often lead to revision surgery.The aim of the proposed project is to develop a new surface coating (biocoating) for implants which allows eliminating/minimizing these complications. T he biocoating represents the multi-layered polyelectrolyte film with incorporated drug-loaded liposomes. The liposomes have a role of reservoirs with biologically active drugs ¿ drugs, which support healing of wound (implantation is done by surgery) or/and antibiotics to prevent bacteria colonization. The use of stimuli-sensitive liposomes or stimuli-sensitive polyelectrolyte film gives opportunity to control liposomes integrity and as a result to control a release of the drug loaded in the liposomes.The main advantages of the biocoating are:a). Drug release may be controlled by ultrasound as external stimulus, which is non-invasive treatment, well focused, and comfortable for a patient;b). Local application of drugs released from biocoating directly to surrounding tissue is advantageous in that high local levels without systemic toxicity can be achieved.The constituents of the film (lipids and polyelectrolytes) are chosen to be biocompatible. The biocoating allows enhancing biocompatibility of implant surf ace using polyelectrolytes promoting specific interaction with proteins and cells.

Original text from CORDIS.

Participants

  • MAX-PLANCK-GESELLSCHAFT ZUR FöRDERUNG DER WISSENSCHAFTEN E.V. · MüNCHENCoordinatorCountry levelGermany

Links

Data: CORDIS, © European Union